The LYCRA Company Invites the Apparel Industry to View “FashionFarmers,” an Innovative Media Campaign Launching on Earth Day
The LYCRA Company, a global leader in developing sustainable fiber and technology solutions for the apparel and personal care industries, has launched an integrated media campaign on Earth Day that promotes the upcoming release of its bio-derived LYCRA® fiber made with QIRA®.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240422182950/en/
The LYCRA Company launches innovative campaign on Earth Day to highlight the company’s plans to bring bio-derived LYCRA® fiber made with QIRA® to market at scale. (Photo: Business Wire)
This sustainable fiber solution will be available in early 2025 and is the result of a unique collaboration with Qore®, producer of QIRA®, a key ingredient in LYCRA® fiber. QIRA® will be made from annually renewable dent corn at a state-of-the-art facility in Iowa. It will be used to make bio-derived LYCRA® fiber at scale, with The LYCRA Company setting a goal to replace up to 30% of its current annual production with the renewable QIRA® ingredient.
The new campaign will help inform the industry about some of the unique advantages of using dent corn grown in Iowa as feedstock for apparel. It features some of the farmers who are growing the corn that will help create the next generation of LYCRA® fiber. At the heart of the “FashionFarmers” campaign are four video documentaries covering various aspects of farming and their relevance to apparel: Regenerative Agriculture, Traceability,Multi-Generational Farming, and Collaboration.
WWD has created a customized digital content hub that showcases the farmers’ stories and related content. The videos will also be promoted on The LYCRA Company’s website and owned social media channels.
“This partnership with LYCRA® and QIRA® lives at the core of the Fairchild brand mission: delivering purposeful content to the fashion industry that will drive businesses forward,” said Amanda Smith, President of FMG. “We are thrilled to be using our global platform to collaborate with the LYCRA® and QIRA® brands to tell this innovation story, and to be able to showcase the impact this fiber technology will have on the future of the industry as a whole.”
The LYCRA Company will amplify its messaging with a six-month media buy across WWD’s network and other select global publications designed to reach sourcing industry leaders, fashion insiders, brands and retailers looking to reduce the environmental impact of their company’s products.
“Our collaboration with Qore® to develop bio-derived LYCRA® fiber made with QIRA® is an important part of our sustainability journey,” said Steve Stewart, The LYCRA Company’s Chief Brand and Innovation Officer. “We introduced the world’s first commercial bio-derived spandex back in 2014 and now, with Qore® as our partner, we’re excited to bring this to market at scale, reducing the carbon emissions of LYCRA® fiber by up to 44%*. This will likewise help our customers lower their carbon footprint.”
This sustainable solution will also deliver equivalent performance, eliminating the need for significant production changes or re-engineering of fabrics or patterns. To reinforce this point, test quantities of bio-derived LYCRA® fiber are currently available, allowing customers to confirm the fiber’s performance properties.
“We are excited to introduce the apparel industry to some of the farmers who are growing corn to help make fashion more sustainable,” said Jon Veldhouse, CEO of Qore® LLC. “This campaign highlights their roles as stewards of the land and reveals their passion for driving positive impact in their communities.”
The LYCRA Company is inviting customers who have expressed interest in adopting bio-derived LYCRA® fiber to Iowa this summer to visit some of the farms and tour the Qore® plant where QIRA® will be made.
Learn more about bio-derived LYCRA® fiber made QIRA® at LYCRA.com/QIRA.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll US Consulting, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
About Qore® LLC
Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. Qore® and QIRA® are trademarks of Qore® LLC. For more information and inquiries visit https://www.myqira.com/
LYCRA® is a trademark of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422182950/en/
Contact information
Karie J. Ford
Karie.J.Ford@lycra.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PQE Group Joins Project-COMFORT to Advance Patient-Centric Blood Collection and Diagnostics30.12.2024 07:50:00 CET | Press Release
PQE Group, a global consulting firm specializing in Life Sciences, is proud to contribute its expertise as a strategic partner in the Project-COMFORT consortium. This innovative public-private partnership, funded by Horizon Europe and supported by the Innovative Health Initiative Joint Undertaking (IHI JU), officially launched in November 2024, marking a transformative shift in blood collection and diagnostics. The ambitious 42-month project brings together 51 organizations from a broad spectrum of sectors, including academia, research institutions, hospitals, foundations, SMEs, medical technology, and pharmaceutical companies, all united by the mission to simplify, reduce the invasiveness of, and increase accessibility to blood collection through cutting-edge, patient-centered microsampling technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241229266268/en/ Follow Project-Comfort LinkedIn Page: https://www.linkedin.
Medical-Fish-Skin Company Kerecis Expands Silicone Fish-Skin Combination Product Range for Surgical and Trauma Wound with SurgiClose® Silicone27.12.2024 20:00:00 CET | Press Release
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of SurgiClose® Silicone, which combines a fish-skin graft and silicone backing for efficient treatment of surgical and trauma wounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241227975454/en/ SurgiClose® Silicone (Photo: Business Wire) SurgiClose® Silicone is a part of the SurgiClose® product family, which is intact fish-skin intended for the management of trauma wounds and surgical wounds in the operating room. The new product is available in two variations, SurgiClose® Silicone Adhesive with borders that overlap the fish-skin underneath and SurgiClose® Silicone Standard with non-overlapping borders. “Applying Kerecis fish-skin to a surgical or trauma wound is a multi-step process that often requires supporting products such as sutures, st
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy27.12.2024 12:00:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1 (≥1). “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “This is the second U.S. approval for TEVIMBRA this year, underscoring its potential to address critical needs in oncology. We remain deeply grateful to the patients, clinicians, and resear
Takeda Announces Approval of HYQVIA ® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia27.12.2024 07:00:00 CET | Press Release
Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan. HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infu
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom